


## Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657)

### Specifications:


Name:	Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free
Description:	Recombinant humanized monoclonal antibody to PD1.
Applications:	ELISA, FACS, Functional Assay, In Vivo
Reactivity:	Human, Cynomolgus Macaque
Host:	Humanized
Clonality:	Monoclonal
Isotype:	IgG4SP - Human IgG4 with S228P mutation
Light Chains:	kappa
Conjugate:	Unconjugated
Purification:	Protein A affinity chromatography.
Concentration:	Reconstitution dependent.
Molecular Weight:	This antibody has a predicted MW of 143.44 kDa.
Purity:	> 95% (by SDS-PAGE and SEC-HPLC).
Product Form:	Lyophilized
Reconstitution:	Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation:	Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage:	Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Disclaimer:	This product is for research use only. It is not intended for diagnostic or therapeutic use.

# Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657)


Images:




SDS-PAGE analysis of Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657) under reducing (R) conditions confirms that the purity of this antibody is greater than 95%.



SEC-HPLC analysis of Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657) confirms that the purity of this antibody is greater than 95%.



Immobilized recombinant human PD1 protein (His tag) at 2 µg/ml is bound by Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657). EC50 = 0.0039 µg/ml.



Pembrolizumab Biosimilar - Anti-PD1 Antibody - Low endotoxin, Azide free (A323657) inhibited the tumor growth of MC38 on human PD-1 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 44.0% at 0.18 mpk at D37.